General MedicationsORALStandard
DEFLAZACORT
DEFLAZACORT
Standard Dose
22.75MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview DEFLAZACORT is listed in Drugs@FDA under application 220042 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient DEFLAZACORT Form and strength SUSPENSION;ORAL - 22.75MG/ML Sponsor ZYDUS LIFESCIENCES Submission history Latest submission status date: 2026-01-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview DEFLAZACORT is listed in Drugs@FDA under application 220042 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient DEFLAZACORT Form and strength SUSPENSION;ORAL - 22.75MG/ML Sponsor ZYDUS LIFESCIENCES Submission history Latest submission status date: 2026-01-13 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.